Abstract:
Background: Docetaxel is a cytotoxic drug used in different types of cancer. However, the tolerance
is marked by hematological toxicity especially neutropenia. Distribution of Docetaxel is assured by
lipoproteins, albumin and α1-acid glycoprotein. It is demonstrated that docetaxel clearance was related
to α1-acid glycoprotein level. Increased estrogen level is associated with decreased plasmatic
concentration of α1-acid glycoprotein, and unbound docetaxel is correlated with α1-acid glycoprotein.
In fact, this study solves the hypothesis that women who have a decreased levels of α1-acid
glycoprotein are more exposed to develop severe toxicities of docetaxel chemotherapy.
Patients: Women diagnosed with breast cancer undergoing chemotherapy by docetaxel
Methods: Pretreatment dosage of α1-acid glycoprotein and check in of the neutropenia and adverse
events of Docetaxel
Results: Thirty patients are included in the study, 23 patients (76,66%) developed neutropenia. α1-acid glycoprotein is correlated to neutropenia (Khi2 18.3, p<0,0001)
Conclusion: α1-acid glycoprotein Level can be considered as independent factor to Docetaxel
toxicity, results to be confirmed by more investigations with large sample.
